The Heads of Medicines Agencies (HMA), is the working forum of heads of human and veterinary regulatory agencies for medicinal products in the EU Member States and the EEA-EFTA States, Iceland, Liechtenstein and Norway. The Agency plays key role as a partner in the European Medicines Regulatory Network.
The HMA adopted a Strategy Paper, which stakeholders were free to comment upon until May 31 2006. The HMA Strategy Paper intends to be a contribution to the debate about the future of the Network. It proposes ways of enhancing the protection of public health and animal welfare in the EEA and claims to complement the existing EMEA Road Map. The Strategy Paper is intended to be a tool for continuous improvement of the Network through a regular communication process between HMA and stakeholders.
The document consists of the following main parts:
an examination of the current regulatory system (its context rather than an in depth analysis of the legal framework)
an analysis of the stakeholders in the network
proposals to enhance the current system
an Action Plan.
Several of EPHA’s members submitted their views on the Strategy Paper, including the Pharmaceutical Group of the EU (PGEU) and International Federation of Anthroposophic Doctors Associations (IVAA), which are attached below.
